Analysts’ Weekly Ratings Updates for Praxis Precision Medicines (PRAX)

Several brokerages have updated their recommendations and price targets on shares of Praxis Precision Medicines (NASDAQ: PRAX) in the last few weeks:

• 5/7/2025 – Praxis Precision Medicines is now covered by analysts at Chardan Capital. They set a “buy” rating and a $80.00 price target on the stock.
• 5/5/2025 – Praxis Precision Medicines had its price target raised by analysts at Wedbush from $26.00 to $28.00. They now have an “underperform” rating on the stock.
• 5/5/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $80.00 price target on the stock.
• 5/1/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $105.00 price target on the stock.
• 4/8/2025 – Praxis Precision Medicines had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $85.00 price target on the stock.

Praxis Precision Medicines Trading Up 0.9%

Shares of Praxis Precision Medicines stock opened at $37.35 on Tuesday. The business’s 50-day moving average price is $35.58 and its 200-day moving average price is $59.38. The firm has a market capitalization of $760.78 million, a PE ratio of -3.63 and a beta of 2.65. Praxis Precision Medicines, Inc. has a 12 month low of $26.70 and a 12 month high of $91.83.

Praxis Precision Medicines (NASDAQ:PRAX) last posted its quarterly earnings results on Friday, May 2nd. The company reported ($3.29) EPS for the quarter, missing the consensus estimate of ($3.20) by ($0.09). Praxis Precision Medicines had a negative return on equity of 54.86% and a negative net margin of 9,409.22%. As a group, analysts predict that Praxis Precision Medicines, Inc. will post -10.22 earnings per share for the current fiscal year.

Institutional Trading of Praxis Precision Medicines

Institutional investors have recently added to or reduced their stakes in the business. Adage Capital Partners GP L.L.C. boosted its holdings in Praxis Precision Medicines by 188.1% during the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,742,758 shares of the company’s stock valued at $65,998,000 after acquiring an additional 1,137,748 shares during the period. Janus Henderson Group PLC raised its holdings in Praxis Precision Medicines by 77.5% in the 4th quarter. Janus Henderson Group PLC now owns 929,523 shares of the company’s stock worth $71,621,000 after purchasing an additional 405,957 shares in the last quarter. Driehaus Capital Management LLC lifted its position in shares of Praxis Precision Medicines by 192.0% in the 1st quarter. Driehaus Capital Management LLC now owns 481,598 shares of the company’s stock worth $18,238,000 after purchasing an additional 316,686 shares during the period. VR Adviser LLC boosted its stake in shares of Praxis Precision Medicines by 40.2% during the 4th quarter. VR Adviser LLC now owns 989,985 shares of the company’s stock valued at $76,189,000 after purchasing an additional 283,854 shares in the last quarter. Finally, Alyeska Investment Group L.P. bought a new stake in shares of Praxis Precision Medicines during the 4th quarter valued at about $17,454,000. 67.84% of the stock is currently owned by hedge funds and other institutional investors.

Praxis Precision Medicines, Inc, a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy.